Genetic biomarker may predict nerve pain side effects associated with prostate cancer treatment

May 13, 2016, H. Lee Moffitt Cancer Center & Research Institute

Taxanes are a group of drugs commonly used to treat cancers of the breast, lung, ovary, or prostate, but its use can be limited by significant side effects. Researchers from Moffitt Cancer Center report prostate cancer patients who have a variation in the VAC14 gene are more susceptible to a side effect called peripheral neuropathy when treated with the taxane docetaxel.

Peripheral neuropathy is a common side effect of taxane treatment. Patients who suffer from this condition have damage to their and experience weakness, numbness and pain usually in their hands or feet and occasionally in other areas of the body. This can limit the use of an otherwise effective cancer treatment.

In a study published online May 3 in the journal Clinical Cancer Research, researchers analyzed the DNA of men who had castrate-resistant and participated in a randomized phase 3 clinical trial that included docetaxel in the . Out of 623 patients from the study, 50 (8.1%) experienced debilitating peripheral neuropathy.

The researchers examined the patients' DNA for genetic variations called single nucleotide polymorphisms (SNPs) that were associated with docetaxel-induced peripheral neuropathy. They discovered that a variation in the VAC14 gene was highly associated with the incidence of docetaxel-induced .

"The genetic variant of VAC14 identified in this study could be useful for understanding the mechanism of docetaxel-induced neuropathy and may be informative for avoiding docetaxel treatment in patients at elevated neuropathy risk," said Howard McLeod, Pharm.D., medical director of the DeBartolo Family Personalized Medicine Institute at Moffitt. "This also offers new drug development strategies to improve the outcomes for cancer patients."

Explore further: Taxane-induced neuropathy not tied to breast cancer outcome

Related Stories

Taxane-induced neuropathy not tied to breast cancer outcome

August 2, 2012
(HealthDay) -- For patients with operable breast cancer, peripheral neuropathy due to adjuvant taxane therapy does not correlate with improved outcomes, according to research published online July 30 in the Journal of Clinical ...

Nerve damage from chemo may affect cancer survivors for years

January 15, 2016
(HealthDay)—Many women who survive cancer have symptoms of chemotherapy-related nerve damage in their feet and hands years after treatment, a new study reveals.

Even after anti-androgen therapy, docetaxel remains useful in prostate cancer

January 11, 2016
A study presented at the 2016 Genitourinary Cancers Symposium shows that 40 percent of patients with castration-resistant metastatic prostate cancer (mCRPC) treated with docetaxel following abiraterone had at least 50 percent ...

Neurofeedback reduces pain, increases quality of life for cancer patients suffering from chemotherapy-induced neuropathy

March 11, 2016
A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and increase quality of life in patients with neuropathic pain.

Researchers identify gene variations that predict chemotherapy side effects

April 9, 2013
Seemingly benign differences in genetic code from one person to the next could influence who develops side effects to chemotherapy, a Mayo Clinic study has found. The study identified gene variations that can predispose people ...

YouTube videos on peripheral nerve pain may misguide patients

October 21, 2015
Researchers who combed YouTube for videos regarding peripheral neuropathy, or nerve damage that causes weakness, numbness, and pain in the hands and feet, found 200 videos, but only about half of them were from healthcare ...

Recommended for you

Researchers create a drug to extend the lives of men with prostate cancer

March 16, 2018
Fifteen years ago, Michael Jung was already an eminent scientist when his wife asked him a question that would change his career, and extend the lives of many men with a particularly lethal form of prostate cancer.

Machine-learning algorithm used to identify specific types of brain tumors

March 15, 2018
An international team of researchers has used methylation fingerprinting data as input to a machine-learning algorithm to identify different types of brain tumors. In their paper published in the journal Nature, the team ...

Higher doses of radiation don't improve survival in prostate cancer

March 15, 2018
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology ...

Joint supplement speeds melanoma cell growth

March 15, 2018
Chondroitin sulfate, a dietary supplement taken to strengthen joints, can speed the growth of a type of melanoma, according to experiments conducted in cell culture and mouse models.

Improved capture of cancer cells in blood could help track disease

March 15, 2018
Tumor cells circulating throughout the body in blood vessels have long been feared as harbingers of metastasizing cancer - even though most free-floating cancer cells will not go on to establish a new tumor.

Area surrounding a tumor impacts how breast cancer cells grow

March 14, 2018
Cancer is typically thought of as a tumor that needs to be removed or an area that needs to be treated with radiation or chemotherapy. As a physicist and cancer researcher, Joe Gray, Ph.D., thinks differently.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.